Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.42 |
| ▸ | FLT1 | P17948 | 4/20 | 0.39 |
| ▸ | FLT4 | P35916 | 4/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813675 | 0.83 | KDR (0.46) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL15315957 | 0.81 | KDR (0.43) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL822887 | 0.80 | KDR (0.41) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL25564159 | 0.77 | KDR (0.46) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL15315970 | 0.77 | KDR (0.51) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL27659057 | 0.76 | P2RX4 (0.46) | KDRFLT1FLT4MAPK9MAPK10 | |
| SCHEMBL15315975 | 0.76 | KDR (0.44) | KDRMAPK9MAPK10 | |
| SCHEMBL15316034 | 0.75 | KDR (0.37) | KDRFLT1FLT4HSD11B1 | |
| SCHEMBL528245 | 0.72 | MAPK9 (0.54) | KDRFLT1FLT4MAPK9MAPK10 | |
| Benzene SCHEMBL27839441 | 0.72 | MAPK9 (0.54) | KDRFLT1FLT4MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130270541-A1 | IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20130270541-A1 | IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130270541-A1 | IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE | NFXL1, NFE2L2, ZC3HAV1L | KDR 215/4885FLT1 1339/4885FLT4 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.